The Prostate Net

02/11/2026

Safety net healthcare refers to providers, clinics, and hospitals that deliver care to low-income, uninsured, or vulnerable populations, regardless of their ability to pay or immigration status. These entities, which include public hospitals, community health centers, and clinics, primarily serve patients reliant on Medicaid, Medicare, or charity care.

In this video regarding the Urologic Oncology study “Prostate cancer-related genetic counseling in a safety-net healthcare setting,” Kalyani Narra, MD, highlighted several system-level factors at JPS Health Network that contributed to high completion rates of genetic counseling visits, despite the access barriers commonly seen in underserved populations.

See details at:

To address high no-show rates typical of safety-net settings, JPS implemented proactive scheduling practices.

02/11/2026

The brain drain continues from the States.

Large proportion worked at Columbia University, which had its grants cut and frozen by the administration of US President Donald Trump.

02/03/2026

Are we winning the War against Cancer?
What are the latest developments in advanced prostate cancer care?
Will AI improve the quality of diagnoses and treatment?

Join the conversation Virgil had with Dr. Joaquin Mateo from Vall d'Hebron Cancer Center to be better informed. Listen to it at: https://www.ivoox.com/en/dr-joaquin-mateo-audios-mp3_rf_167507695_1.html

Check out our archive of previous programs at: http://theprostatenet.org/media/EnglishRadio/

02/03/2026

"A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer."

Read the article at:

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer.

01/29/2026

The subject was Prostate Cancer when Dr. Joaquin Mateo from Vall d'Hebron Institute of Oncology joined Virgil to talk about new developments in managing advanced stage disease and how technology is being used to provide personalized detection and therapeutic care.

See the discussion at: https://www.youtube.com/live/jmVVJA2hqbk?si=PTBd1gLl-DPdwTDu

01/27/2026

Cancer seems like it’s been with us forever, but what is the state of our progress against this disease.

Joining us tomorrow to talk about the global war against prostate cancer, and if we're winning, is a physician/scientist, former Chair of the ESMO Translational Research and Precision Medicine Working Group, and Group Leader of the Prostate Cancer Research Group at Vall d’Hebron Institute of Oncology in Barcelona, Dr. Joaquin Mateo.

Tune in on Wednesday when we will broadcast Live from 4:00 to 5:00PM CET (10:00AM EST) at:
Radio: 102.5FM - La Marina Cat
Internet: http://lamarina.cat/endirecte/
YouTube: https://www.youtube.com/

Share this with networks so they can be better informed as to the risks they face and the emergent treatments available.

01/26/2026

Exclusive: key NIH review panels due to lose all members by the end of 2026

Thirteen of the agency’s advisory councils, which must review grant applications before funding is awarded, are on track to have no voting members.

Federal law requires these panels to review applications for all but the smallest grants before funding can be awarded, meaning that the ability of those institutes to issue new grants could soon be frozen.

Dozens of scientists who were poised to fill these vacancies were dismissed last year by the administration of US President Donald Trump, Nature reported in July.

At the advisory council for the National Institute on Minority Health and Health Disparities, the final voting members’ terms end next month. Without extraordinary action, the council will have no members by its May meeting, when it is scheduled to review grant applications submitted as early as last September — meaning those applications would be effectively frozen.

Read the article at:

Thirteen of the agency’s advisory councils, which must review grant applications before funding is awarded, are on track to have no voting members.

01/23/2026

Investigators from University Hospital Düsseldorf in Germany are seeking to validate a personalized counseling and monitoring strategy for patients who are at an increased risk of prostate cancer due to positive family history or pathogenic genetic variants.

The prospective registry, called ProFam-Risk (NCT05681416), is enrolling participants across 3 cohorts: men without known prostate cancer who have an increased familial risk of prostate cancer (defined as at least 2 first-degree relatives with prostate cancer at any age or 1 first-degree relative with early onset prostate cancer); men without known prostate cancer who have confirmed pathogenic germline variants associated with prostate cancer; and men 40 years and older who have diagnosed prostate cancer and a familial and/or genetic risk.

Across these cohorts, the study aims to identify likely pathogenic or pathogenic variants or novel cancer signaling pathways, evaluate multiparametric MRI (mpMRI) for prostate cancer prevention in high-risk individuals, and assess psychosocial factors as part of the psychosocial subproject ProFam-Psych.

According to the authors, “ProFam-Risk may serve as a proof-of-concept project by demonstrating the feasibility, clinical utility, and added value of an integrated, interdisciplinary high-risk screening approach, including patient acceptance, psychological outcomes, and adherence to follow-up recommendations.”

This study represents the increasing importance of understanding the full complexity of prostate cancer risk.

Read the article at:

The prospective registry is evaluating a personalized counseling and monitoring strategy for patients who are at an increased risk of prostate cancer due to positive family history or pathogenic genetic variants.

01/22/2026

US science after a year of Trump:

More than 7,800 research grants terminated or frozen. Some 25,000 scientists and personnel gone from agencies that oversee research. Proposed budget cuts of 35% — amounting to US$32 billion.

These are just a few of the ways in which Donald Trump has downsized and disrupted US science since returning to the White House last January.

Read the article at:

A series of graphics reveals how the Trump administration has sought historic cuts to science and the research workforce.

01/21/2026

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side effects of long-term hormone therapy.

The Phase 2 trial, called ANDROMEDA, is the first study to directly compare two types of PSMA-targeted radiopharmaceuticals-lutetium-177–PSMA-617 (lutetium Lu 177 vipivotide tetraxetan) and actinium-225–PSMA-617-when used alongside stereotactic body radiotherapy (SBRT), a focused form of radiation that treats all detectable tumors.

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side e...

01/20/2026

Mount Sinai Tisch Cancer Center is sponsoring a day of learning, dialogue and community connection to confront cancer disparities and celebrate the power of collaboration.

The attached flyer details the schedule for the day and how to register.

We encourage all those in the NYC Metro area to attend in person, but if you are outside of the city, state, or country it's possible to participate remotely as noted as follows:

You are invited to a Zoom webinar!
When: Feb 4, 2026 09:30 AM Eastern Time (US and Canada)
Topic: 02/04/2026 - 09:30AM - World Cancer Day

Join from PC, Mac, iPad, or Android:
https://mountsinai.zoom.us/j/95924545243
Passcode:287238

Please share with your networks.

01/16/2026

Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer (PCa) screening, prediction models do not predict time-to-event end points or adjust for patient life expectancy.
New model enhances prediction of prostate cancer-specific mortality

In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while accounting for other-cause mortality (OCM).

This model more accurately stratifies patients’ long-term risk of PCSM after prostate-specific antigen (PSA) screening compared with existing calculators, particularly over extended follow-up.

This PCSM prognostic model was developed from long-term clinical trial data, was externally validated in a large national cohort, and may be used to improve interpretation of PSA results.

Read for more info:

Background: Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer (PCa) screening, prediction models do not predict time-to-event end points or adjust for patient life expectancy. Objective: To develop, externally validate, and compare to existing tools a novel prognostic....